Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Natalizumab (NTZ) is sometimes discontinued in patients with multiple sclerosis, mainly due to concerns about the risk of progressive multifocal leukoencephalopathy. However, NTZ interruption may result in recrudescence of disease activity